Dronning Eufemias gate 30,Oslo 0191

Type of Company



Investment Services & Portfolio Management

Company Description

DNB AM is a GARP-oriented, occasionally contrarian investment manager which uses both active and passive investment processes to invest globally in a variety of asset classes including equity, debt, money market instruments, commodities and alternative investments. They invest across market-caps and sectors, with the bulk of their assets in Norwegian blue chip equity. Research is shared with fellow asset management subsidiaries, in particular through a global program of company visits. Tactical asset allocation is based on a proprietary scenario-generating model developed jointly with academics.The firm's investment approach for fixed-income and money market instruments takes into accounts short-term trends and long-term strategy. Index funds are geared towards maximal cost effectiveness. Actively managed portfolios are diversified, uncorrelated and favor liquid markets. They use disciplined review and exit processes including stop-losses.Their equity investment process is top-down and consists of stock picking informed by market trend analysis and a macroeconomic view. The firm seeks to identify turning points in the evolution of key indicators. They manage diversified and uncorrelated equity portfolios and aim to invest in companies outperforming their peers on a global level. Their alternative portfolios are invested in equity following a long/short strategy.

Contact Data
Trying to get in touch with decision makers at Luminor? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Head of Norwegian Equities

Head of Global Technology Equities

Head of Renewable Energy

Head of Global Energy

Head of Fixed Income

Head of Strategic Asset Allocation


Paths to Luminor
Potential Connections via
Relationship Science
Recent Transactions
Details Hidden

Ciena Corp. purchases Cyan, Inc.

Transaction Clients

Advised on Ciena Corp. purchases Cyan, Inc.

Details Hidden

Sana Pharma Medical AS develops topical analgesic products. It develops products against various chronic pain conditions, including osteoarthritis of the knee. Its product 2PX provides clinical benefit in the management of both nociceptive and neuropathic pain. The company was founded in 2002 and is headquartered in Oslo, Norway.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Luminor. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Luminor's profile does not indicate a business or promotional relationship of any kind between RelSci and Luminor.
  • be_ixf; php_sdk; php_sdk_1.4.15